# 119-hr-7837: Most Favored Patient Act of 2026

119-hr-7837, Most Favored Patient Act of 2026, is a 119th Congress bill sponsored by Rep. Meuser, Daniel [R-PA-9] (R-PA); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-hr-7837
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-7837
- Congress: 119
- Title: Most Favored Patient Act of 2026
- Status: introduced
- Introduced: 2026-03-05
- Sponsor: Rep. Meuser, Daniel [R-PA-9] (R-PA)
- Cosponsors: 0
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**Creates a Most Favored Nations drug-pricing test that ties certain U.S. drug prices to lower prices abroad.** This bill would direct the Center for Medicare and Medicaid Innovation to run an MFN pricing model for specified Part B and Part D drugs and to add the model to program rules beginning in 2029. - Manufacturers would have to offer the MFN price to MFN-eligible individuals and to pharmacies, mail-order dispensers, hospitals, clinicians, and other providers. They must also report pricing and sales data to the Secretary, and the Secretary can suspend MFN rules for a drug until April 1, 2029 if a covered agreement is likely. - People enrolled in Medicaid, Medicare Part D, or receiving Part B drugs would be eligible to receive covered drugs at the MFN price when dispensed or administered. Pharmacies, hospitals, and clinicians are explicitly included as points of access. - The MFN price is defined as the second-lowest applicable net price among eight reference countries and is adjusted for purchasing power. The test applies to drugs sold in two or more reference countries and would run for 5 years.

## Provisions PRIA read

- Most Favored Nation drug prices for Medicare, Medicaid: benefit, medium. This bill would create a five-year Most Favored Nation (MFN) drug pricing test starting January 1, 2029. Manufacturers without a covered agreement would have to give MFN prices to eligible Medicare and Medicaid patients and to pharmacies and providers who dispense or administer the drugs. The MFN p…

## Related bills

- 119-hr-9237: Take Care of America’s Veterans Act
- 119-hr-6644: 21st Century ROAD to Housing Act
- 119-hr-137: TCJA Permanency Act
- 119-hr-3633: Digital Asset Market Clarity Act
- 119-hr-2570: Maximum Pressure Act
- 119-hr-6955: Main Street Capital Access Act

## Sources
- [119-hr-7837 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/7837)

## Related
- [119-hr-9237: Take Care of America’s Veterans Act](https://policyrisk.com/legislation/119-hr-9237)
- [119-hr-6644: 21st Century ROAD to Housing Act](https://policyrisk.com/legislation/119-hr-6644)
- [119-hr-137: TCJA Permanency Act](https://policyrisk.com/legislation/119-hr-137)
- [119-hr-3633: Digital Asset Market Clarity Act](https://policyrisk.com/legislation/119-hr-3633)
- [119-hr-2570: Maximum Pressure Act](https://policyrisk.com/legislation/119-hr-2570)
- [119-hr-6955: Main Street Capital Access Act](https://policyrisk.com/legislation/119-hr-6955)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-7837 (as of 2026-04-21).